dr. chase on toxicities with niraparib in ovarian cancer
Published 4 years ago • 225 plays • Length 0:46Download video MP4
Download video MP3
Similar videos
-
1:38
dr. chase on niraparib as frontline maintenance therapy in ovarian cancer
-
2:41
dr. chase on toxicities of treatments for ovarian cancer
-
3:08
ovarian cancer: optimizing treatment with niraparib
-
3:14
personalized dosing of niraparib in ovarian cancer
-
4:29
case 1: use of niraparib in ovarian cancer
-
6:31
diane davis' story: ovarian cancer survivor
-
40:03
ovarian cancer patient | sara's story: getting through surgery, chemo, parp inhibitor (video 2/3)
-
50:32
precision medicine for ovarian cancer (2021)
-
2:26
dr. mirza discusses niraparib dose modifications for ovarian cancer patients with low body weight
-
6:31
prima: frontline niraparib maintenance therapy in ovarian cancer
-
3:10
overview of engot-ov16/nova of niraparib in ovarian cancer and why the results were not surprising
-
1:14
dr. chase discusses risk factors in gynecologic cancers
-
0:57
dr. mirza on impact of niraparib in ovarian cancer
-
1:14
dr. arend on niraparib with bevacizumab in ovarian cancer
-
58:46
learn all about parp inhibitors with dr jon krell, consultant medical oncologist
-
1:26
parp inhibitors for maintenance therapy in ovarian cancer
-
1:18
dr. pothuri on patient-reported outcomes with niraparib in advanced ovarian cancer
-
1:30
dr. mirza on niraparib efficacy across ovarian cancer subgroups
-
6:32
case 1: use of niraparib in ovarian cancer
-
18:37
ongoing clinical trials with parp inhibitors in ovarian cancer
-
5:13
treating ovarian cancer with niraparib: the nova trial
-
6:57
niraparib maintenance for recurrent ovarian cancer